Alphatec Holdings, Inc. ATEC
We take great care to ensure that the data presented and summarized in this overview for Alphatec Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATEC
View all-
Black Rock Inc. New York, NY7.61MShares$77 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.46MShares$55.2 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN5.42MShares$54.8 Million5.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.16MShares$52.2 Million0.03% of portfolio
-
American Century Companies Inc Kansas City, MO4.17MShares$42.2 Million0.04% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$31.7 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL2.64MShares$26.7 Million0.4% of portfolio
-
Fred Alger Management, LLC New York, NY2.62MShares$26.5 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.53MShares$25.6 Million0.23% of portfolio
-
State Street Corp Boston, MA2.37MShares$24 Million0.0% of portfolio
Latest Institutional Activity in ATEC
Top Purchases
Top Sells
About ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
Insider Transactions at ATEC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 24
2024
|
John Todd Koning CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
37,500
-8.7%
|
$450,000
$12.82 P/Share
|
Mar 14
2024
|
Evan Bakst |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$195,000
$13.53 P/Share
|
Mar 07
2024
|
Quentin S. Blackford |
BUY
Open market or private purchase
|
Direct |
20,000
+3.37%
|
$240,000
$12.83 P/Share
|
Mar 06
2024
|
Tyson Eliot Marshall GENERAL COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
9,225
-3.02%
|
$119,925
$13.16 P/Share
|
Mar 01
2024
|
Tyson Eliot Marshall GENERAL COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
11,825
-3.73%
|
$153,725
$13.3 P/Share
|
Mar 01
2024
|
John Todd Koning CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
121,601
-22.01%
|
$1,580,813
$13.3 P/Share
|
Feb 27
2024
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
32,365
-4.94%
|
$485,475
$15.19 P/Share
|
Feb 27
2024
|
Scott Lish CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
31,075
-5.77%
|
$466,125
$15.19 P/Share
|
Feb 26
2024
|
Craig E Hunsaker EVP, PEOPLE & CULTURE |
SELL
Open market or private sale
|
Direct |
41,560
-3.38%
|
$623,400
$15.05 P/Share
|
Feb 24
2024
|
Patrick Miles CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
88,169
-1.55%
|
$1,322,535
$15.27 P/Share
|
Feb 21
2024
|
Scott Lish CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
11,963
-2.17%
|
$179,445
$15.34 P/Share
|
Feb 21
2024
|
Scott Lish CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+5.46%
|
-
|
Feb 21
2024
|
Tyson Eliot Marshall GENERAL COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
27,778
+8.06%
|
-
|
Feb 21
2024
|
Patrick Miles CEO |
BUY
Grant, award, or other acquisition
|
Direct |
81,794
+1.42%
|
-
|
Feb 21
2024
|
Craig E Hunsaker EVP, PEOPLE & CULTURE |
BUY
Grant, award, or other acquisition
|
Direct |
41,190
+3.24%
|
-
|
Feb 21
2024
|
David Sponsel EVP, SALES |
SELL
Open market or private sale
|
Direct |
17,820
-2.65%
|
$267,300
$15.34 P/Share
|
Feb 21
2024
|
David Sponsel EVP, SALES |
BUY
Grant, award, or other acquisition
|
Direct |
35,063
+4.96%
|
-
|
Feb 21
2024
|
John Todd Koning CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+5.43%
|
-
|
Feb 20
2024
|
Patrick Miles CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
154,702
-2.68%
|
$2,320,530
$15.52 P/Share
|
Feb 20
2024
|
Craig E Hunsaker EVP, PEOPLE & CULTURE |
SELL
Open market or private sale
|
Direct |
77,255
-6.1%
|
$1,158,825
$15.16 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.38M shares |
---|---|
Open market or private purchase | 70.8K shares |
Open market or private sale | 1.3M shares |
---|---|
Payment of exercise price or tax liability | 364K shares |